trending Market Intelligence /marketintelligence/en/news-insights/trending/TUDOYqXgxnf3_mGEVd3BHg2 content esgSubNav
In This List

GLG Pharma Q1 loss narrows YOY

Case Study

Broad Environmental Data Guides an Insurer’s Journey to Net Zero


Broadcast deal market recap, Q2'22


Japan M&A By the Numbers: Q1 2022


Next in Tech | Episode 77: Language in Tech

GLG Pharma Q1 loss narrows YOY

GLG Pharma S.A. said its normalized net income for the first quarter came to a loss of 7,440 zlotys, compared with a loss of 15,440 zlotys in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

Reported net income totaled a loss of 11,900 zlotys, or a loss of 0 groszy per share, compared to a loss of 24,700 zlotys, or a loss of 3 groszy per share, in the prior-year period.

As of May 17, US$1 was equivalent to 3.86 zlotys.